1680.1000 3.40 (0.20%)
NSE May 30, 2025 15:31 PM
Volume: 37,338
 

1680.10
0.20%
ICICI Securities Limited
Metropolis’ Q3FY25 result was impacted by lower sales from institutional biz (2% impact on revenue) and muted growth in acute ailment tests. In last 4 years, Metropolis has widened its lab network by 68% to 209 labs in 9MFY25.
Metropolis Healthcare Ltd. is trading above its 50 day SMA of 1644.9
More from Metropolis Healthcare Ltd.
Recommended